NZ511720A - Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of African and American trypanosomiasis - Google Patents

Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of African and American trypanosomiasis

Info

Publication number
NZ511720A
NZ511720A NZ511720A NZ51172099A NZ511720A NZ 511720 A NZ511720 A NZ 511720A NZ 511720 A NZ511720 A NZ 511720A NZ 51172099 A NZ51172099 A NZ 51172099A NZ 511720 A NZ511720 A NZ 511720A
Authority
NZ
New Zealand
Prior art keywords
ester
treatment
halogen
sulphate
independently
Prior art date
Application number
NZ511720A
Other languages
English (en)
Inventor
Clarence Nathaniel Ahlem
James Martin Frincke
Patrick T Prendergast
Krupakar Paul Thadikonda
Original Assignee
Hollis Eden Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hollis Eden Pharmaceuticals filed Critical Hollis Eden Pharmaceuticals
Publication of NZ511720A publication Critical patent/NZ511720A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
NZ511720A 1998-11-24 1999-11-24 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of African and American trypanosomiasis NZ511720A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10992398P 1998-11-24 1998-11-24
US12408799P 1999-03-11 1999-03-11
US12605699P 1999-03-23 1999-03-23
PCT/US1999/028079 WO2000032201A2 (fr) 1998-11-24 1999-11-24 Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement du paludisme et le traitement de la trypanosiomase africaine ou americaine

Publications (1)

Publication Number Publication Date
NZ511720A true NZ511720A (en) 2002-12-20

Family

ID=27380739

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ511720A NZ511720A (en) 1998-11-24 1999-11-24 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of African and American trypanosomiasis

Country Status (13)

Country Link
EP (1) EP1135138A2 (fr)
JP (1) JP2002531407A (fr)
KR (2) KR20010101073A (fr)
CN (1) CN1348373A (fr)
AP (1) AP1584A (fr)
AU (2) AU776853B2 (fr)
BR (1) BR9915623A (fr)
CA (1) CA2356539A1 (fr)
HK (1) HK1043319A1 (fr)
IL (1) IL142941A0 (fr)
NZ (1) NZ511720A (fr)
OA (1) OA11715A (fr)
WO (1) WO2000032201A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129282A1 (en) 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
WO2001003681A2 (fr) * 1999-07-08 2001-01-18 Prendergast Patrick T Utilisation de flavones, de coumarines et de composes associes dans le traitement d'infections
DE60045751D1 (de) 1999-09-30 2011-04-28 Harbor Biosciences Inc Therapeutische Behandlung androgenrezeptorbedingter Leiden
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
US7910755B2 (en) 2004-09-29 2011-03-22 Harbor Biosciences, Inc. Stem cell expansion and uses
US8217025B2 (en) 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
KR100786126B1 (ko) * 2007-08-14 2007-12-18 주식회사 아바코 비접촉 방식에 의한 피절단물의 평탄도를 유지하는스크라이브 헤드 장치 및 그 스크라이브 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
CN1216470A (zh) * 1996-04-17 1999-05-12 帕特里克·T·普伦德加斯特 脱氢表雄酮组合治疗方法
WO1998047516A1 (fr) * 1997-04-17 1998-10-29 Prendergast Patrick T Therapie combinee mettant en application des 17-cetosteroides et des inhibiteurs d'interleukine, ou interleukine-10 eventuellement avec des inhibiteurs d'interleukine

Also Published As

Publication number Publication date
AP1584A (en) 2006-03-01
BR9915623A (pt) 2001-08-14
IL142941A0 (en) 2002-04-21
WO2000032201A2 (fr) 2000-06-08
HK1043319A1 (zh) 2002-09-13
OA11715A (en) 2005-03-14
WO2000032201A3 (fr) 2000-12-21
AU2004237812B2 (en) 2007-11-29
AU776853B2 (en) 2004-09-23
CA2356539A1 (fr) 2000-06-08
KR20070004149A (ko) 2007-01-05
KR20010101073A (ko) 2001-11-14
JP2002531407A (ja) 2002-09-24
AP2001002182A0 (en) 2001-06-30
EP1135138A2 (fr) 2001-09-26
CN1348373A (zh) 2002-05-08
AU2004237812A1 (en) 2005-01-13
AU1745300A (en) 2000-06-19

Similar Documents

Publication Publication Date Title
NZ511720A (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of African and American trypanosomiasis
KR960702431A (ko) 과콜레스테롤혈증 치료제로서의 N-아실 술팜산 에스테르(또는 티오에스테르), N-아실 술폰아미드 및 N-술포닐 카르밤산 에스테르(또는 티오에스테르)(N-Acyl Sulfamic Acid Esters(or Thioesters), N-Acyl Sulfonamides, and N-Sulfonyl Carbamic Acid Esters(or Thioesters) as Hypercholesterolemic Agents)
MX9304587A (es) Derivados de 4-aza-5alfa-androstan-3-ona sustituidos en la posicion 17-beta, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
AU1039688A (en) 3(2h)pyridazinone, process for its preparation and antagonistic agent against srs-a containing it
BR9810657A (pt) "processo de preparação de um per-hidroisoindol substituìdo"
NO995590D0 (no) 20-Aryl-5<alfa>-pregnan-derivater
SG76479A1 (en) Pleuromutilin derivatives
FI91070B (fi) Parannus androsta-1,4-dieeni-3,17-dionin 6-metyleenijohdannaisten synteesissä
DK0988312T3 (da) 17beta-allyloxy(thio)alkyl-androstanderivater til modulering af meiose
TR199901089T2 (xx) Aminhidrofl�oridler ve bunlar�n oral hijyen preparasyonlar� olarak kullan�mlar�.
ES2058849T3 (es) Benzanilidas.
NO964216D0 (no) Ester- og karbamatderivater av azoloner som er kraftige midler mot Helicobacter
DE3569729D1 (en) 3-aminoazetidine, its salts, process for their preparation and intermediates
HU9202100D0 (en) New 16-methyl-pregna-1,4-diene-3,20-dione derivatives
NO931716L (no) Fremgangsmaate for fremstilling av n,n-dialkylglycaminforbindelser
ES2022421B3 (es) Nuevos productos esteroides comportando, en posicion 23, un radical sulfinilo, proceso de preparacion, aplicacion en la preparacion de productos de la serie 20 -cetoprenona y de los intermedios de esta aplicacion
FI960730A0 (fi) Indolijohdannaiset 5alfa-reduktaasi-1-inhibiittoreina
PT94906A (pt) Processo para a preparacao de novos derivados n-(23-vincristinoilicos) e n-(5'-noranidro-23-vinblastinoilicos) do acido 1-amino-metil-fosfonico
TW254937B (en) Benzocycloheptene derivative and process for preparation thereof
DK1137660T3 (da) 22S-hydroxycholesta-8,14-dienderivater med meioseregulerende aktivitet
DE69531507D1 (de) Zwischenprodukte zur herstellung einer pharmazeutisch aktiven verbindung
MY102002A (en) Phenethylamine derivatives
GT199300022A (es) Procedimientos para la sintesis de glicosidos esteroidales
MY105475A (en) Steroid compounds.
MX170821B (es) Procedimiento para la preparacion de 3-[2-[4-(4-fluorobenzoil)-1-piperidinil]etil]-2,4-(1h,3h)-quinazolindiona

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)